Biotech

Jason Mitchell Co-Founder, Director and Chief Executive Officer, HempFusion Wellness Inc. ("HempFusion" or the "Company") (TSX: CBD.U), and his team joined David Chelich Sector Head, Global Energy and Diversified Industries, TMX Group, to celebrate the Company's new listing on Toronto Stock Exchange and open the market.


HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to approximately 4,000 retailers across all 50 states of the United States and select international locations. The Company's diverse product portfolio comprises 46 SKUs including tinctures, proprietary FDA Drug Listed Over The Counter (OTC) Topicals, Doctor/Practitioner Lines and more. https://www.hempfusion.com/

For Market Openings: Media may pick up a feed from the TOC (television operations centre) for all market open ceremonies. The feed is named TSX Transmit 1 (SD-SDI) and is produced at the TMX Broadcast Centre and sent live to the TOC. To pick up the feed via the Dejero network, please contact avservices@tmx.com . The client feature video will begin playing on the TMX media wall at approximately 9:27 a.m. ET and the markets will open with the sound of a siren at 9:30 a.m. ET .

Date: Friday, January 22, 2021
Time: 9:00am - 9:30am
Place:  Virtually Broadcast

SOURCE TMX Group Limited

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/January2021/22/c8250.html

News Provided by Canada Newswire via QuoteMedia

How to Invest in Biotechnology

How to Invest in Biotechnology

Investors interested in the life sciences are well aware of the importance that biotechnology and biotech companies have in this exciting market.

From finding cures for diseases to feeding future generations, there are many areas of day-to-day life that are influenced by players in the biotechnology space.

But how can investors gain exposure to biotechnology? And what investing options exist in the sector? Here’s a brief overview of how to invest in biotechnology, from stocks to watch to exchange-traded funds (ETFs).

Keep reading...Show less

AbbVie to Host Third-Quarter 2022 Earnings Conference Call

ABBVie (NYSE: ABBV) will announce its third-quarter 2022 financial results on Friday, October 28, 2022 before the market opens. ABBVie will host a live webcast of the earnings conference call at 8 a.m. CT . It will be accessible through ABBVie's Investor Relations website investors.ABBVie.com . An archived edition of the session will be available later that day.

About AbbVie

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus' Proprietary Safety Switch System

- Bristol Myers Squibb to receive access to Autolus' RQR8 safety switch for use in cell therapy programs -

- Autolus to receive an upfront payment, with potential for near term option exercise fees and development milestone payments plus royalties -

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Kite Receives U.S. FDA Approval of Viral Vector Manufacturing Facility in Southern California to Produce Commercial Product

-- Viral Vector Facility Further Strengthens Vertical Integration of Kite's Global CAR T-cell Therapy Manufacturing Network, Supports Growing Demand of Company's Blood Cancer Treatments --

-- Kite is the Only Cell Therapy Company with In-House Viral Vector Manufacturing Capabilities for Both Commercial Products and Clinical Trials --

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx Inhibits and also Promotes Reversal of Mechanisms Leading to Cardiac Fibrosis

Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx Inhibits and also Promotes Reversal of Mechanisms Leading to Cardiac Fibrosis

Data Presented at The Annual Scientific Meeting of the Heart Failure Society of America September 30th, 2022

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of cardiovascular diseases ("CVD"), announced today that study results demonstrate the active pharmaceutical ingredient ("API") in CardiolRx™ inhibits and also promotes the reversal of mechanisms known to play a role in the occurrence and development of fibrotic CVD. The data were presented by its research collaborators from Houston Methodist DeBakey Heart & Vascular Center at The Annual Scientific Meeting of the Heart Failure Society of America ("HFSA2022").

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
The Gummy Project Continues Strategic Expansion in US Hotel Sector After Receiving Purchase Order from Virgin Hotels Chicago to Become Supplier of Gummy Products for Guest Room Mini-Bars

The Gummy Project Continues Strategic Expansion in US Hotel Sector After Receiving Purchase Order from Virgin Hotels Chicago to Become Supplier of Gummy Products for Guest Room Mini-Bars

  • The Gummy Project's Peachy Bees and Watermelon Sharks expected to be featured for sale in all 250 guest rooms at the Virgin Hotel Chicago.
  • Purchase order continues The Gummy Projects strategic expansion in the Canadian and US Hotel sector.

The Gummy Project (CSE: GUMY) (FSE: 0OS0) (OTCQB: GUMYF) ("GUMY" or the "Company") is pleased to announce that it has received a purchase order from the Virgin Hotels Chicago to become a supplier of gummies for each of the hotel's 250 guest room mini-bars.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×